PHAXIAM Therapeutics S.A. (PHXM.PA)
| Previous Close | 1.7940 |
| Open | 1.7680 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.7680 - 1.7900 |
| 52 Week Range | 1.5000 - 5.0000 |
| Volume | |
| Avg. Volume | 10,480 |
| Market Cap | 18.464M |
| Beta (5Y Monthly) | 1.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9800 |
| Earnings Date | Nov 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.10 |
GlobeNewswirePHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.
GLORIA, the world's 1st phase II phage therapy study in the treatment of Prosthetic Joint Infections (PJI) related to Staphylococcus aureusThe clinical protocol also being submitted to the European health authorities and the MHRA in the UKPatients recruitment scheduled to start in Q1 2025 for clinical data readout expected in Q3 2026 Lyon (France), November 04, 2024 – 6:00 pm CET - PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments
- GlobeNewswire
Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024
Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) voting rightsDecember 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 9516 226 702March 29, 20246 075 1056 226 9386 226 689April 30, 20246 075 1056 226 9326 226 683May 31, 20246 075 1056 226 9896 226 740July 1, 20249 980 66810
